Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bishop

Showing results (921-930 of 1,042) with videos related to

Pageof 105
Sort By:
Blood|February 1, 2012
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantationNancy M Hardy, Vicki Fellowes, Jeremy J Rose, et al.
Bioorganic & Medicinal Chemistry|January 1, 1997
Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylationA K Mallams, F G Njoroge, R J Doll, et al.
Journal of Medicinal Chemistry|November 21, 1998
(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agentF G Njoroge, A G Taveras, J Kelly, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 18, 2023
Rare variants found in clinical gene panels illuminate the genetic and allelic architecture of orofacial cleftingKimberly K Diaz Perez, Sarah W Curtis, Alba Sanchis-Juan, et al.
Cancer Discovery|April 5, 2019
Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in HematopoiesisJong Jin Jeong, Xiaorong Gu, Ji Nie, et al.
Journal of Medicinal Chemistry|April 4, 1998
Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazineA K Mallams, R R Rossman, R J Doll, et al.
Blood|September 26, 2012
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?Ulrike Bacher, Evgeny Klyuchnikov, Jennifer Le-Rademacher, et al.
Blood|February 22, 2013
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantationDaniel H Fowler, Miriam E Mossoba, Seth M Steinberg, et al.
Open Forum Infectious Diseases|August 28, 2025
Usefulness and Limitations of Polymerase Chain Reaction (PCR) for the Diagnosis and Management of Toxoplasmosis Following Allogeneic Hematopoietic Cell Transplant: Single-center Experience With 31 Patients Over 16 YearsMary M Czech, Theresa Jerussi, Sanchita Das, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 4, 2011
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable changeSandra A Mitchell, David Jacobsohn, Kimberly E Thormann Powers, et al.
Pageof 105

Showing results (921-930 of 1,042) with videos related to

Sort By:
Pageof 105
Blood|February 1, 2012
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantationNancy M Hardy, Vicki Fellowes, Jeremy J Rose, et al.
Bioorganic & Medicinal Chemistry|January 1, 1997
Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylationA K Mallams, F G Njoroge, R J Doll, et al.
Journal of Medicinal Chemistry|November 21, 1998
(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agentF G Njoroge, A G Taveras, J Kelly, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 18, 2023
Rare variants found in clinical gene panels illuminate the genetic and allelic architecture of orofacial cleftingKimberly K Diaz Perez, Sarah W Curtis, Alba Sanchis-Juan, et al.
Cancer Discovery|April 5, 2019
Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in HematopoiesisJong Jin Jeong, Xiaorong Gu, Ji Nie, et al.
Journal of Medicinal Chemistry|April 4, 1998
Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazineA K Mallams, R R Rossman, R J Doll, et al.
Blood|September 26, 2012
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?Ulrike Bacher, Evgeny Klyuchnikov, Jennifer Le-Rademacher, et al.
Blood|February 22, 2013
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantationDaniel H Fowler, Miriam E Mossoba, Seth M Steinberg, et al.
Open Forum Infectious Diseases|August 28, 2025
Usefulness and Limitations of Polymerase Chain Reaction (PCR) for the Diagnosis and Management of Toxoplasmosis Following Allogeneic Hematopoietic Cell Transplant: Single-center Experience With 31 Patients Over 16 YearsMary M Czech, Theresa Jerussi, Sanchita Das, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 4, 2011
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable changeSandra A Mitchell, David Jacobsohn, Kimberly E Thormann Powers, et al.
Pageof 105